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BARDOXOLONE METHYL: A POTENTIAL THERAPEUTIC FOR THE PREVENTION OF ANTI-
PSYCHOTIC DRUG-INDUCED OBESITY? D Camer, CJ Bell, Y Yu, A Szabo, F Fernandez, CHL Dinh, and 
XF Huang, Centre for Translational Neuroscience, School of Medicine, University of Wollongong and 
Illawarra Health and Illawarra Health and Medical Research Institute, Wollongong, ANSTO LifeSciences, 
Australian Nuclear Science and Technology Organisation, NSW, Faculty of Social Sciences, University of 
Wollongong, Wollongong, NSW, Australia, Schizophrenia Research Institute, Sydney, NSW, Australia 
 
INTRODUCTION: Antipsychotic drug treatment is known to cause obesity in psychiatric patients. Recently, 
a derivative of oleanolic acid, bardoxolone methyl (BM) has been shown to have therapeutic benefits in 
reducing inflammation, a key contributing factor to the development of obesity. However, effects of BM on 
the development of obesity and associated comorbidities have not been studied. METHODS: C57BL/6J 
male mice were fed a lab chow (LC) (5% of energy as fat), HF (40% of energy as fat), or HF diet 
supplemented with 10 mg/kg/day BM orally for 21 weeks. Novel object recognition testing was performed to 
assess recognition memory. Signaling molecules including inflammatory mediators were examined via 
western blotting in the hypothalamus and prefrontal cortex of mice. RESULTS AND DISCUSSION: BM 
administration prevented HF diet-induced obesity by preventing increases in food intake, body weight, 
hyperleptinemia, and hyperinsulemia in mice fed a HF diet (p<0.05). In the hypothalamus, BM 
administration prevented HF diet-induced impairments to leptin signaling by modulating energy balance 
regulation molecules involved in downstream JAK2-Akt-FOXO1 signaling and prevented increases in 
inflammatory mediators such as TNFα and PTP1B. In addition, BM treatment prevented HF diet-induced 
decline in recognition memory (p<0.001). In the prefrontal cortex of HF diet fed mice, BM administration 
improved downstream BDNF-TrkB-Akt signaling and prevented HF diet-induced increases in the protein 
levels of inflammatory molecules, pJNK and PTP1B (p<0.05). These results identify a potential novel 
application for BM in preventing HF diet-induced obesity and associated comorbidities. Furthermore, 
preliminary testing in antipsychotic-treated rats indicates a potential therapeutic capacity of BM to prevent 
antipsychotic-induced obesity. RESEARCH SUPPORT: This research was supported by Diabetes 
Australia. 
 
